**Core Concept**
The patient is likely experiencing insulin resistance due to truncal obesity, a common feature of polycystic ovary syndrome (PCOS) or metabolic syndrome. Gliconil, an oral hypoglycemic drug, is used to manage type 2 diabetes mellitus.

**Why the Correct Answer is Right**
Gliconil is a thiazolidinedione (TZD) class of medication, which acts by activating peroxisome proliferator-activated receptor-gamma (PPAR-γ). Activation of PPAR-γ increases the expression of genes involved in glucose and lipid metabolism, leading to improved insulin sensitivity. This action helps to reduce insulin resistance, thereby lowering blood glucose levels.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect as it refers to a different class of medications, such as sulfonylureas, which act by stimulating insulin release from the pancreatic beta cells.
* **Option B:** This option is incorrect as it refers to a class of medications like DPP-4 inhibitors, which act by inhibiting dipeptidyl peptidase-4, thereby increasing the levels of incretin hormones that stimulate insulin release.
* **Option C:** This option is incorrect as it refers to a different class of medications, such as alpha-glucosidase inhibitors, which act by inhibiting the intestinal absorption of glucose.

**Clinical Pearl / High-Yield Fact**
TZDs like gliconil are known to have a risk of fluid retention and heart failure, particularly in patients with pre-existing cardiac conditions. It is essential to monitor patients closely for signs of fluid retention and adjust the medication or discontinue it if necessary.

**Correct Answer:** C. PPAR-γ.